| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:109-112.)
© 2008 American Heart Association, Inc.
Editorial |
From the Cardiac MR Center, University Hospital Zurich and Childrens University Hospital, Zurich, Switzerland.
Correspondence to Juerg Schwitter, MD, FESC, University Hospital Zurich, Cardiology Clinics, Raemistrasse 100, CH-8091 Zurich, Switzerland. E-mail juerg.schwitter{at}usz.ch
Key Words: Editorials contrast media imaging magnetic resonance imaging metabolism spectroscopy
| Introduction |
|---|
|
|
|---|
Article p 140
Flögel et al elegantly exploit a primary mode of action of inflammatory cells (ie, phagocytosis of potentially harmful agents), which in this case happens to be a magnetic resonance (MR)–active contrast medium. Another remarkable aspect of their work is the use of the naturally occurring stable fluorine isotope 19F as the MR-active nucleus for imaging. Why is this unique? This 19F-MR imaging strategy takes advantage of the fact that after administration of 19F-containing compounds, any signal detected in the body via MR imaging (MRI) is emanating from the injected contrast medium (ie, an extraordinary contrast-to-noise ratio [CNR] is present, because no background signal from the body is detected by 19F-MR imaging). If the MR scanner is thereafter tuned to the 1H resonance frequency, conventional MRI occurs, and all morphological and functional information on the organ can be acquired. Because this imaging is performed in the same location and with the same equipment, registration is ideal; this allows "fusion imaging" to be used to combine specific signals of inflammatory cells (19F imaging) with organ function and anatomy (conventional 1H imaging).
The performance of the authors imaging approach is impressive. In addition to an excellent CNR, the signals are received from voxels as small as 0.5x0.5x2 mm3, and the 19F-containing contrast medium consisting of nanoparticles loaded with perfluorocarbons is biologically inert. Moreover, in the study, these perfluorocarbons were monitored in the body for up to 6 days and were detected not only in the ischemic territories undergoing repair but also in the postoperative sutures and in the liver, where the signals persisted for several months. Considering these features and the high sensitivity of this technique in detecting populations as small as a few hundred macrophages, this approach is a promising candidate for future research. It will likely provide new insight into inflammatory processes in the cardiovascular system and may also be applicable in clinical situations.
| Translation of Animal Multinuclei MRI to Humans: General Considerations |
|---|
|
|
|---|
0.2 µmol per voxel of 0.5x0.5x2 mm3 at 9.4 T, in humans at 3 T and employing a voxel size of 5x5x5 mm3 in a head coil,
4 mmol would be detected with the same SNR of 20 after the same acquisition duration of 20 minutes. The 19F technique with excellent CNR can measure slow processes, which do not require high temporal resolution, and hence it allows for long acquisition times and thereby increases SNR. Accordingly, this 19F technique represents a powerful application of MR at one end of the MRI spectrum, where slow processes are to be probed (see Figure 2).
|
|
On the other end of the spectrum, another nucleus, 13C, is present, which allows for very fast MRI of specific processes with high temporal and spatial resolution (Figure 2). For fast processes, long signal acquisition is not feasible. The 13C techniques exploit the hyperpolarization of these 13C compounds, which yield SNRs that are up to 10 000 times higher than can be obtained with conventional 1H MRI.2 Although 19F nuclei in perfluorocarbons remain in the body for weeks and allow (in principle) for very long acquisition times, 13C-labeled compounds "lose" their hyperpolarized state with short half-lives (for [13C]pyruvate,
25 seconds), and imaging can only be performed for 1 to 2 minutes. This means that the sensitivity of the measurements obtained using 13C cannot be increased by increasing the signal acquisition time, and the technique is ideal to study short-lived processes with extremely high sensitivity. Assuming 5% polarization of 13C at the time of imaging in the target voxel of 5x5x5 mm3 in a 3-T scanner using a head coil and measuring for 400 milliseconds (!),
100 µmol of the 13C compound per voxel would be detected. In a recent canine study performed with hyperpolarized [13C]pyurvate in a 3-T scanner, an estimated 5 µmol of [13C]pyruvate was detected per voxel of 5x5x5 mm3 (assuming a homogeneous distribution of the injected [13C]pyruvate in the body
30 seconds after administration).3 Accordingly, this hyperpolarized 13C approach allows for near-real-time noninvasive metabolic imaging at resolutions in the millimeter dimension.4 Not only is the initial SNR enormous as generated by the hyperpolarization, it also allows monitoring of the metabolic fate of, eg, injected [13C]pyruvate metabolized into [13C]lactate, [13C]alanine, and others by means of the serially acquired spectra. This unique feature was recently exploited to invasively monitor pH in tumor tissue.5 As for 19F imaging, this hyperpolarized 13C imaging yields excellent CNRs, as any signal detected in the body is uniquely emanating from the compound injected and its metabolic products. In pig experiments, this technique was used to probe the citric acid cycle in mitochondria after subjecting the animals to short episodes of ischemia.6 In this setting, a "metabolic memory" was identified, which is a potentially adaptive mechanism to preserve function in the postischemic period.6 During congestive heart failure, metabolic adaptations occur that can initiate a vicious cycle (eg, those that occur during diabetic congestive heart failure).7,8 This 13C technique "fused" with conventional 1H cardiac MRI could yield unique information in congestive heart failure on cardiac energetics, metabolic alterations, myocardial function and perfusion, as well as viability.
In conventional 1H imaging, where no hyperpolarization is applied, only 4 to 5 spins out of 1 million (
0.0005%) are contributing to the MR signal at the thermal equilibrium at 1.5 T (fully relaxed state), for which the abundance of water (
80 mol/L concentration) in biological tissue is compensating. In addition, conventional gadolinium-based contrast media can facilitate recovery of magnetization after excitation, thereby allowing for faster relaxation (ie, faster imaging). Gadolinium chelates coupled to specific targeting molecules are used for molecular imaging, which is covered in detail elsewhere,9 whereas this editorial focuses on cardiac magnetic resonance exploiting nuclei other than 1H. Unfortunately, in 1H imaging, the magnetization cannot be increased beyond full relaxation by any contrast medium, and hence, an additional increase in signal (and thus an increase in sensitivity for 1H nuclei) can only be achieved by prolongation of signal acquisition. As a consequence, spatially restricted processes of a certain duration that require a minimum temporal and/or spatial resolution of imaging10 inherently limit the amount of available signal in 1H imaging.11 Here, 13C imaging can extend the capability of MR through hyperpolarization (20% to 30% of spins at injection deliver signal!).12 At this end of the spectrum, involving fast processes in the micromolar concentration range, 13C imaging can be used. At the opposite end of the spectrum, the 19F imaging is complementary, allowing for excellent CNR with high sensitivity for long-lasting processes such as inflammation, cell migration, differentiation, and others. All of this highly specific information of 19F and 13C imaging can be combined with conventional 1H imaging to yield information on such matters as tissue and organ morphology, function, perfusion,13,14 viability,15 flows,16 endothelial function,17–19 targeted imaging,20 and cell tracking21 (see Figure 2). Fusion of these different modalities (ie, a multiparametric MRI approach) will have a major impact in research and perhaps in clinical cardiology as well.
| Multiparametric MRI: Future Perspectives |
|---|
|
|
|---|
| Acknowledgments |
|---|
Disclosures
Dr Schwitter is a consultant for the MR-IMPACT program and for research activities on cardiovascular applications of hyperpolarized 13C compounds sponsored by GE Healthcare.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Ardenkjaer-Larsen J, Fridlund B, Gram A, Hansson G, Hansson L, Lerche M, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of >10 000 times in liquid-state NMR. Proc Natl Acad Sci U S A. 2003; 100: 10158–10163.
3. Zierhut M, Yen Y, Chen A, Bok R, Albers M, Zhang V, Tropp J, Park I, Vigneron D, Kurhanewicz J, Hurd R, Nelson S. How does dose of hyperpolarized 13C1-pyruvate affect metabolic results in dog prostate? Paper presented at: 16th Scientific Meeting of ISMRM; May 3–9, 2008; Toronto, Canada. Abstract 172.
4. Golman K, int Zandt R, Thaning M. Real-time metabolic imaging. Proc Natl Acad Sci U S A. 2006; 103: 11270–11275.
5. Louie A, Hueber M, Ahrens E, Rothbaecher U, Moats R, Jacobs R, Fraser S, Meade T. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol. 2000; 18: 321–325.[CrossRef][Medline] [Order article via Infotrieve]
6. Schwitter J. Myocardial perfusion imaging by cardiac magnetic resonance. J Nucl Cardiol. 2006; 13: 841–854.[CrossRef][Medline] [Order article via Infotrieve]
7. Opie L. The metabolic vicious cycle in heart failure. Lancet. 2004; 364: 1733–1734.[CrossRef][Medline] [Order article via Infotrieve]
8. Murray A, Anderson R, Watson G, Radda G, Clarke K. Uncoupling proteins in human heart. Lancet. 2004; 364: 1786–1788.[CrossRef][Medline] [Order article via Infotrieve]
9. Jaffer F, Weissleder R. Seeing within: molecular imaging of the cardiovascular system. Circ Res. 2004; 94: 433–445.
10. Balaban R, Arai A. Function, metabolic, and flow heterogeneity of the heart: the view is getting better. Circ Res. 2001; 88: 265–267.
11. Johansson L, Bjoernerud A, Ahlstroem H, Ladd D, Fujii D. A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging. 2001; 13: 615–618.[CrossRef][Medline] [Order article via Infotrieve]
12. Mansson S, Johansson E, Magnusson P, Chai C, Petersson J, Stahlberg F, Golman K. 13-C imaging: a new diagnostic platform. Eur Radiol. 2006; 16: 57–67.[CrossRef][Medline] [Order article via Infotrieve]
13. Schwitter J, Nanz D, Kneifel S, Bertschinger K, Büchi M, Knüsel PR, Marincek B, Lüscher TF, von Schulthess GK. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation. 2001; 103: 2230–2235.
14. Schwitter J, Wacker C, van Rossum A, Lombardi M, Al-Saadi N, Ahlstrom H, Dill T, Larsson HB, Flamm S, Marquardt M, Johansson L. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008; 29: 480–489.
15. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000; 343: 1445–1453.
16. Schwitter J, DeMarco T, Kneifel S, von Schulthess GK, Jörg MC, Arheden H, Rühm S, Stumpe K, Buck A, Parmley WW, Lüscher TF, Higgins CB. Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: a comparison with positron emission tomography. Circulation. 2000; 101: 2696–2702.
17. Sorensen MB, Collins P, Ong PJ, Webb CM, Hayward CS, Asbury EA, Gatehouse PD, Elkington AG, Yang GZ, Kubba A, Pennel DJ. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation. 2002; 106: 1646–1651.
18. Silber HA, Bluemke DA, Ouyang P, Du YP, Post WS, Lima JA. The relationship between vascular wall shear stress and flow-mediated dilation: endothelial function assessed by phase-contrast magnetic resonance angiography. J Am Coll Cardiol. 2001; 38: 1859–1865.
19. Schwitter J, Oelhafen M, Wyss BM, Kozerke S, Amann-Vesti B, Lüscher TF, Boesiger P. 2D-spatially-selective real-time magnetic resonance imaging for the assessment of microvascular function and its relation to the cardiovascular risk profile. J Cardiovasc Magn Reson. 2006; 8: 759–769.[CrossRef][Medline] [Order article via Infotrieve]
20. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v) beta3-integrin-targeted nanoparticles. Circulation. 2003; 108: 2270–2274.
21. Hill J, Dick A, Raman V, Thompson R, Yu Z, Hinds K, Pessanha B, Guttman M, Varney T, Martin B, Dunbar C, McVeigh E, Lederman R. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation. 2003; 108: 1009–1014.
This article has been cited by other articles:
![]() |
Z. A. Fayad, L. Razzouk, K. C. Briley-Saebo, and V. Mani Iron Oxide Magnetic Resonance Imaging for Atherosclerosis Therapeutic Evaluation: Still "Rusty?" J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2051 - 2052. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |